Solésence Launches New Skin Health Technologies: WHSPR™ and Chromalüm™
Rhea-AI Summary
Solésence (Nasdaq:SLSN) launched two proprietary skin health platforms, WHSPR™ and Chromalüm™, now commercially available through finished goods for brand partners worldwide. The technologies expand Solésence's ingredient portfolio and support OTC-grade sensitive skin and environmental protection claims across skincare, suncare, and color cosmetics.
WHSPR™ is an advanced allantoin delivery system that enables high-concentration, stable use in anhydrous formats and supports OTC skin and lip protectant claims. Clinical studies showed statistically significant improvements, including up to 63% redness reduction and 112% immediate hydration. Chromalüm™ integrates precision color with Kleair™ to provide broad-spectrum SPF and targeted HEV protection for high-sheer and full-coverage color cosmetics.
Positive
- WHSPR™ clinical data show up to 63% redness reduction at 48 hours
- WHSPR™ enables high-concentration allantoin use in anhydrous product formats
- WHSPR™ supports OTC skin and lip protectant claims for brand partners
- Immediate hydration improvements with WHSPR™ reach up to 112% above baseline
- Chromalüm™ plus Kleair™ delivers targeted HEV protection in the 400–450 nm range
- Chromalüm™ supports high-SPF, water-resistant color cosmetics across coverage levels
Negative
- None.
News Market Reaction – SLSN
In the May 11 session, SLSN gained 11.11%, reflecting a significant positive market reaction. Argus tracked a peak move of +4.8% during that session. Argus tracked a trough of -16.9% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. Trading volume was elevated at 2.2x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 28 | Earnings date notice | Neutral | -5.1% | Scheduled Q1 2026 results and conference call announcement. |
| Apr 27 | Board appointment | Positive | +14.9% | Added independent director with capital markets and governance experience. |
| Mar 31 | Earnings results | Positive | +5.4% | Reported record 2025 revenue growth and improved Q4 gross margin. |
| Mar 19 | Earnings date notice | Neutral | +2.3% | Announced date and logistics for FY 2025 results call. |
| Feb 26 | Management hire | Positive | -1.5% | Named VP of Brand Partnerships to drive turnkey solutions growth. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent operational and governance news generally coincided with modestly positive price reactions, while one partnership hire saw a small decline.
Over the last six months, Solésence reported record 2025 revenue of $62.1 million with improving Q4 gross margin, and communicated its Transform & Transcend initiative (Mar 31, 2026). Governance updates included a new independent director on Apr 27, 2026, followed by an 8-K on Apr 29, 2026. The company also regularly pre-announced earnings dates. The current launch of WHSPR™ and Chromalüm™ fits the broader strategy of expanding patented skin-health technology and supporting prestige beauty brand partners.
Key Terms
otc skin protectant monograph regulatory
anhydrous technical
fda otc monograph regulatory
hev medical
gras-status regulatory
broad-spectrum sun protection medical
water-resistant technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
New platform technologies enable OTC-grade sensitive skin claims in previously inaccessible anhydrous formats and bring environmental protection deeper into the color cosmetics assortment
ROMEOVILLE, Ill., May 11, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN) a leader in scientifically-driven health care solutions across beauty and life science categories, today announced the commercial availability of two proprietary platform technologies: WHSPR™ and Chromalüm™. Both technology platforms are available through finished goods for brand partners globally, and represent a significant expansion of the Company's ingredient technology portfolio.
The launch of WHSPR™ and Chromalüm™ advances Solésence's mission to deliver joy through innovation, inclusivity, and the science of beautiful skin. Each platform was developed to address longstanding formulation constraints within health-infused beauty. Consistent with the Company's vertically integrated model, each technology platform is embedded within Solésence's finished goods offering, allowing brand partners to access differentiated product claims, expanded category reach, and clinically validated performance.
WHSPR™: Advanced Allantoin Delivery for Sensitive Skin
WHSPR™, which has received multiple patents in the United States and globally, is a delivery system for allantoin, which is a well-known skin health ingredient on the OTC skin protectant monograph. WHSPR™ enables the use of allantoin at high concentrations with stability, including in anhydrous product formats such as serums, balms, and face and lip oils, where stability and solubility constraints have historically prevented its effective application. By embedding WHSPR™ within its finished goods, Solésence allows brand partners to access OTC skin health claims and sensitive skin-focused products across skincare, suncare, and color cosmetics categories.
Independent clinical studies demonstrated that WHSPR™ delivers statistically significant improvements across all primary endpoints, with 100 percent of study panelists showing measurable improvement in skin barrier recovery, barrier strength, hydration, and redness reduction. Specific outcomes include up to 63 percent reduction in redness at 48 hours compared to no reduction in untreated control, up to 36 percent improvement in skin barrier recovery at 48 hours compared to 4 percent in untreated control, 23 percent improvement in skin barrier strength compared to no improvement in untreated control, and immediate hydration improvements of up to 112 percent above baseline, with up to 18 percent sustained over two weeks.
WHSPR™ supports skin protectant and lip protectant claims under the applicable FDA OTC monograph, enabling brand partners to substantiate regulatory-compliant marketing positions in product categories that have previously been inaccessible for allantoin-based claims. Because Solésence delivers these benefits through finished goods, partners receive products that are fully formulated, clinically supported, and commercially ready, with the aesthetic sensorial profile expected of a premium daily-use cosmetic.
Chromalüm™: Precision Color and HEV Protection for SPF Color Cosmetics
Chromalüm™ is a high-brilliance precision color technology designed to work in conjunction with the Company’s globally patented, award-winning Kleair™ technology. When combined with Solésence Kleair™, the system enables the integration of broad-spectrum sun protection — including targeted high-energy visible, or HEV, light protection in the 400 to 450 nanometer range — into color cosmetics without compromising color quality or aesthetic performance. Leveraging globally accepted GRAS-status colorants alongside Kleair™, Chromalüm™ provides brand partners with a fully integrated color and protection system for product categories where achieving efficacious SPF and HEV protection in high-sheer formulas has historically been difficult.
The technology supports both high-sheer and full-coverage formulations across a broad range of product formats, and is compatible with Solésence Kleair™ to enable fully integrated system formulation. Chromalüm™ also supports high-SPF and water-resistant formula development, extending its applicability to active and sport-oriented color cosmetic products. Preclinical data demonstrates best-in-class HEV protection performance relative to comparable available technologies. As with all Solésence technologies, Chromalüm™ is made available to brand partners through finished goods, with Solésence handling formulation, manufacturing, and quality assurance end to end.
Since the first Solésence brand partner product launch in 2018, the Company has supported dozens of beauty brands across skincare, suncare, and color cosmetics categories on a global basis. The commercial launch of WHSPR™ and Chromalüm™ further extends Solésence's suite of transformative technologies and reinforces the Company's vertically integrated model — enabling brand partners to access breakthrough innovation, fully realized in finished goods, through a single manufacturing relationship.
“When we explore new ingredient technologies, we start with the end consumer in mind, and what those consumers’ needs are,” commented Dr. Harry Sarkas, Chief Scientific Officer at Solésence. “Together, WHSPR™ and Chromalüm™ expand the range of products that can deliver key skin health claims around protection and healing, removing the barriers that have historically limited where skin health innovation can go.”
“The convergence of health, wellness, and beauty is reshaping what consumers expect and creating a significant commercial opportunity for brands that can substantiate their claims,” said Kevin Cureton, President and Chief Executive Officer of Solésence. “WHSPR™ and Chromalüm™ open product categories and formats that were simply out of reach before now. They also expand our ability to participate in adjacent categories, including hair and scalp care, in the future. We believe that represents a meaningful growth opportunity, and we are excited to bring new and innovative products to market with our brand partners.”
For more information about WHSPR™ and Chromalüm™, or to explore a brand partnership, please contact Solésence at solesence.com.
About Solésence, Inc.
Solésence, Inc. (Nasdaq: SLSN), is a leader in scientifically-driven health care solutions across beauty and life science categories. With a mission to deliver joy through innovation, inclusivity and the science of beautiful skin, we have redefined mineral-based sun protection by maximizing transparency, effectiveness, aesthetics, and wearability — empowering individuals to embrace beauty on their own terms. Combining best-in-class skin health solutions with the celebration of self-care, we allow brands to deliver unique product claims and attributes by seamlessly integrating protection, prevention, and treatment technologies into daily use products. Learn more at solesence.com.
Forward-Looking Statements
This press release contains words such as “expects,” “shall,” “will,” “believes,” and similar expressions that are intended to identify forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements in this announcement are made based on the Company’s current beliefs, known events and circumstances at the time of publication, and as such, are subject in the future to unforeseen risks and uncertainties that could cause the Company’s results of operations, performance, and achievements to differ materially from current expectations expressed in, or implied by, these forward-looking statements. These risks and uncertainties include, without limitation, the following: a decision by a customer to cancel a purchase order or supply agreement in light of the Company’s dependence on a limited number of key customers; uncertain demand for, and acceptance of, the Company’s engineered materials, ingredients, and fully formulated products; the Company’s manufacturing capacity and product mix flexibility in light of customer demand; the Company’s limited marketing experience; changes in development and distribution relationships; the impact of competitive products and technologies; the Company’s dependence on patents and protection of proprietary information; the resolution of litigation in which the Company may become involved; the impact of any potential new government regulations that could be difficult to respond to or too costly to comply with while remaining financially viable; the ability of the Company to maintain an appropriate electronic trading venue; and other factors described in the Company’s Form 10-K filed March 31, 2026. In addition, the Company’s forward-looking statements could be affected by general industry and market conditions and growth rates. Except as required by federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties, or other contingencies.
Media Contact:
media@solesence.com
Investor Relations Contact:
investors@solesence.com
